CING
Cingulate Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.10
−2.30%Aug 13, 2026, 12:30 UTC
Cingulate Inc. reported its financial results for the second quarter ended June 30, 2026.
Source:Jul 14, 2026, 00:00 UTC
Cingulate Inc. appointed Zhanpeng "Frederick" Jiang as chairman of the Audit Committee of the Board of Directors, effective July 9, 2026.
Jul 14, 2026, 00:00 UTC
Cingulate Inc. promoted Shane J. Schaffer to Chief Executive Officer and chairman of the Board of Directors, effective July 9, 2026.
Jul 14, 2026, 00:00 UTC
Cingulate Inc. elected Jeff Hargroves as a Class II director and appointed him as lead independent director, effective July 9, 2026.
Jun 16, 2026, 12:00 UTC
Cingulate Inc. was issued its first company-owned U.S. patent for its lead ADHD asset CTx-1301.
Source:Jun 2, 2026, 12:00 UTC
The FDA issued a Complete Response Letter to Cingulate for its NDA for CTx-1301 for ADHD treatment, with no clinical safety or efficacy concerns but CMC-related requests.